BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//TrialSonar//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TrialSonar · $VRTX readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by TrialSonar. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06696443-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270125
DTEND;VALUE=DATE:20270126
SUMMARY:Suzetrigine readout (P3) · Vertex Pharmaceuticals Incorporated $VR
 TX
DESCRIPTION:Evaluation of the Long-term Safety and Effectiveness of Suzetri
 gine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DP
 N)\n\nPrimary completion date: 2027-01-25 (estimated)\nPhase 3 · Cardio-M
 et · Diabetic Peripheral Neuropathic Pain\nEnrollment: 455 · Sites: 65\n
 \nPrimary completion = last participant's primary-endpoint data collected\
 ; topline results usually follow weeks to months later. Sponsor-reported\,
  often an estimate. Not investment advice.\n\nhttps://trialsonar.netlify.a
 pp/radar.html?nct=NCT06696443\nhttps://clinicaltrials.gov/study/NCT0669644
 3
URL:https://datacutoff.com/radar.html?nct=NCT06696443
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06619860-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270325
DTEND;VALUE=DATE:20270326
SUMMARY:VX-993 readout (P2) · Vertex Pharmaceuticals Incorporated $VRTX
DESCRIPTION:Evaluation of Efficacy and Safety of VX-993 for Pain Associated
  With Diabetic Peripheral Neuropathy\n\nPrimary completion date: 2027-03-2
 5 (estimated)\nOriginally planned: 2026-04 (+11.8 months)\nPhase 2 · Card
 io-Met · Diabetic Peripheral Neuropathic Pain\nEnrollment: 300 · Sites: 
 47\n\nPrimary completion = last participant's primary-endpoint data collec
 ted\; topline results usually follow weeks to months later. Sponsor-report
 ed\, often an estimate. Not investment advice.\n\nhttps://trialsonar.netli
 fy.app/radar.html?nct=NCT06619860\nhttps://clinicaltrials.gov/study/NCT066
 19860
URL:https://datacutoff.com/radar.html?nct=NCT06619860
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05331183-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270406
DTEND;VALUE=DATE:20270407
SUMMARY:ELX/TEZ/IVA readout (P3) · Vertex Pharmaceuticals Incorporated $VR
 TX
DESCRIPTION:Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA
 ) Long-term Safety and Efficacy in Subjects Without F508del\n\nPrimary com
 pletion date: 2027-04-06 (estimated)\nOriginally planned: 2025-03 (+25.2 m
 onths)\nPhase 3 · Rare · Cystic Fibrosis\nEnrollment: 297 · Sites: 81\n
 \nPrimary completion = last participant's primary-endpoint data collected\
 ; topline results usually follow weeks to months later. Sponsor-reported\,
  often an estimate. Not investment advice.\n\nhttps://trialsonar.netlify.a
 pp/radar.html?nct=NCT05331183\nhttps://clinicaltrials.gov/study/NCT0533118
 3
URL:https://datacutoff.com/radar.html?nct=NCT05331183
CATEGORIES:Rare,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07231419-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270406
DTEND;VALUE=DATE:20270407
SUMMARY:Suzetrigine readout (P3) · Vertex Pharmaceuticals Incorporated $VR
 TX
DESCRIPTION:Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain
  Associated With Diabetic Peripheral Neuropathy\n\nPrimary completion date
 : 2027-04-06 (estimated)\nPhase 3 · Cardio-Met · Diabetic Peripheral Neu
 ropathic Pain\nEnrollment: 734 · Sites: 75\n\nPrimary completion = last p
 articipant's primary-endpoint data collected\; topline results usually fol
 low weeks to months later. Sponsor-reported\, often an estimate. Not inves
 tment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT07231419
 \nhttps://clinicaltrials.gov/study/NCT07231419
URL:https://datacutoff.com/radar.html?nct=NCT07231419
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06628908-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Suzetrigine readout (P3) · Vertex Pharmaceuticals Incorporated $VR
 TX
DESCRIPTION:Evaluation of Efficacy and Safety of Suzetrigine for Pain Assoc
 iated With Diabetic Peripheral Neuropathy\n\nPrimary completion date: 2027
 -05-31 (estimated)\nPhase 3 · Cardio-Met · Diabetic Peripheral Neuropath
 ic Pain\nEnrollment: 1100 · Sites: 76\n\nPrimary completion = last partic
 ipant's primary-endpoint data collected\; topline results usually follow w
 eeks to months later. Sponsor-reported\, often an estimate. Not investment
  advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT06628908\nhtt
 ps://clinicaltrials.gov/study/NCT06628908
URL:https://datacutoff.com/radar.html?nct=NCT06628908
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05329649-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270606
DTEND;VALUE=DATE:20270607
SUMMARY:CTX001 readout (P3) · Vertex Pharmaceuticals Incorporated $VRTX
DESCRIPTION:Evaluation of Safety and Efficacy of CTX001 in Pediatric Partic
 ipants With Severe Sickle Cell Disease (SCD)\n\nPrimary completion date: 2
 027-06-06 (estimated)\nOriginally planned: 2026-05 (+13.2 months)\nPhase 3
  · Rare · Sickle Cell Disease\, Hydroxyurea Failure\, Hydroxyurea Intole
 rance\nEnrollment: 13 · Sites: 7\n\nPrimary completion = last participant
 's primary-endpoint data collected\; topline results usually follow weeks 
 to months later. Sponsor-reported\, often an estimate. Not investment advi
 ce.\n\nhttps://datacutoff.com/radar.html?nct=NCT05329649\nhttps://
 clinicaltrials.gov/study/NCT05329649
URL:https://datacutoff.com/radar.html?nct=NCT05329649
CATEGORIES:Rare,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05477563-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270609
DTEND;VALUE=DATE:20270610
SUMMARY:CTX001 readout (P3) · Vertex Pharmaceuticals Incorporated $VRTX
DESCRIPTION:Evaluation of Efficacy and Safety of a Single Dose of CTX001 in
  Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle 
 Cell Disease\n\nPrimary completion date: 2027-06-09 (estimated)\nOriginall
 y planned: 2025-02 (+28.2 months)\nPhase 3 · Rare · Beta-Thalassemia\, T
 halassemia\, Hematologic Diseases\nEnrollment: 26 · Sites: 6\n\nPrimary c
 ompletion = last participant's primary-endpoint data collected\; topline r
 esults usually follow weeks to months later. Sponsor-reported\, often an e
 stimate. Not investment advice.\n\nhttps://datacutoff.com/radar.ht
 ml?nct=NCT05477563\nhttps://clinicaltrials.gov/study/NCT05477563
URL:https://datacutoff.com/radar.html?nct=NCT05477563
CATEGORIES:Rare,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07161037-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270722
DTEND;VALUE=DATE:20270723
SUMMARY:AGLOW readout (P2) · Vertex Pharmaceuticals Incorporated $VRTX
DESCRIPTION:Phase 2a Study of VX-407 in Participants With ADPKD Who Have a 
 Subset of PKD1 Gene Variants (AGLOW)\n\nPrimary completion date: 2027-07-2
 2 (estimated)\nPhase 2 · Cardio-Met · Autosomal Dominant Polycystic Kidn
 ey Disease (ADPKD)\nEnrollment: 26 · Sites: 43\n\nPrimary completion = la
 st participant's primary-endpoint data collected\; topline results usually
  follow weeks to months later. Sponsor-reported\, often an estimate. Not i
 nvestment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT0716
 1037\nhttps://clinicaltrials.gov/study/NCT07161037
URL:https://datacutoff.com/radar.html?nct=NCT07161037
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06460506-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:ELX/TEZ/IVA readout (P3) · Vertex Pharmaceuticals Incorporated $VR
 TX
DESCRIPTION:Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in C
 ystic Fibrosis Participants 12 Months of Age and Older\n\nPrimary completi
 on date: 2027-09-30 (estimated)\nPhase 3 · Rare · Cystic Fibrosis\nEnrol
 lment: 50 · Sites: 18\n\nPrimary completion = last participant's primary-
 endpoint data collected\; topline results usually follow weeks to months l
 ater. Sponsor-reported\, often an estimate. Not investment advice.\n\nhttp
 s://trialsonar.netlify.app/radar.html?nct=NCT06460506\nhttps://clinicaltri
 als.gov/study/NCT06460506
URL:https://datacutoff.com/radar.html?nct=NCT06460506
CATEGORIES:Rare,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05356195-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20271114
DTEND;VALUE=DATE:20271115
SUMMARY:CTX001 readout (P3) · Vertex Pharmaceuticals Incorporated $VRTX
DESCRIPTION:Evaluation of Safety and Efficacy of CTX001 in Pediatric Partic
 ipants With Transfusion-Dependent β-Thalassemia (TDT)\n\nPrimary completi
 on date: 2027-11-14 (estimated)\nOriginally planned: 2026-05 (+18.5 months
 )\nPhase 3 · Rare · Beta-Thalassemia\, Thalassemia\, Genetic Diseases\, 
 Inborn\nEnrollment: 16 · Sites: 6\n\nPrimary completion = last participan
 t's primary-endpoint data collected\; topline results usually follow weeks
  to months later. Sponsor-reported\, often an estimate. Not investment adv
 ice.\n\nhttps://datacutoff.com/radar.html?nct=NCT05356195\nhttps:/
 /clinicaltrials.gov/study/NCT05356195
URL:https://datacutoff.com/radar.html?nct=NCT05356195
CATEGORIES:Rare,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
